CJ Bioscience, Inc. (KOSDAQ:311690)

CJ Bioscience Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,557	10,339	8,309	64,095	49,324	62,060
Short-Term Investments	36,394	40,500	67,000	-	-	18,020
Cash & Short-Term Investments	40,951	50,839	75,309	64,095	49,324	80,080
Cash Growth	-33.18%	-32.49%	17.50%	29.95%	-38.41%	103.89%
Accounts Receivable	-	418.8	72.57	160.91	303.82	233.62
Other Receivables	-	432.46	623.2	178.66	523.06	474.16
Receivables	-	851.26	695.77	339.57	826.88	707.78
Inventory	242.15	185.13	128.75	157.82	76.16	145.83
Prepaid Expenses	-	218.73	294.56	355.71	446.57	259.18
Other Current Assets	1,607	384.56	333.6	262.22	258.72	362.03
Total Current Assets	42,800	52,478	76,762	65,210	50,932	81,555
Property, Plant & Equipment	5,444	6,637	8,907	12,707	14,364	9,856
Long-Term Investments	2	2	2	2	2	0
Other Intangible Assets	11,750	11,778	12,499	12,397	1,016	114.13
Other Long-Term Assets	392.82	1,442	1,439	811.16	25,075	24,830
Total Assets	60,389	72,337	99,610	91,128	91,389	116,355

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	-	378.32	220.83	122.82	336.65	287.75
Accrued Expenses	-	2,229	3,234	3,966	3,996	140.94
Short-Term Debt	7,882	6,984	6,365	3,971	23,588	18,441
Current Portion of Leases	-	1,932	1,824	1,869	1,547	1,361
Other Current Liabilities	6,969	3,035	6,882	4,793	5,511	3,606
Total Current Liabilities	14,851	14,558	18,525	14,722	34,979	23,836
Long-Term Leases	-	1,495	1,162	2,692	3,831	4,088
Pension & Post-Retirement Benefits	65.21	-	-	65.47	-	-
Other Long-Term Liabilities	3,727	2,645	2,166	2,152	2,924	577.4
Total Liabilities	18,643	18,698	21,853	19,633	41,734	28,502

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	6,533	6,533	6,533	4,556	2,939	2,937
Additional Paid-In Capital	189,419	189,419	189,419	151,426	108,066	112,186
Retained Earnings	-154,681	-143,313	-119,067	-85,951	-62,738	-28,035
Comprehensive Income & Other	474.56	1,001	872.04	1,465	1,389	765.25
Shareholders' Equity	41,745	53,639	77,757	71,496	49,655	87,853
Total Liabilities & Equity	60,389	72,337	99,610	91,128	91,389	116,355

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	7,882	10,411	9,351	8,533	28,966	23,891
Net Cash (Debt)	33,069	40,427	65,958	55,562	20,357	56,190
Net Cash Growth	-37.61%	-38.71%	18.71%	172.93%	-63.77%	1501.15%
Net Cash Per Share	2531.62	3094.21	7112.48	7843.75	3463.50	13214.21
Filing Date Shares Outstanding	13.07	13.07	13.07	9.11	5.88	5.87
Total Common Shares Outstanding	13.07	13.07	13.07	9.11	5.88	5.87
Working Capital	27,949	37,920	58,236	50,488	15,953	57,718
Book Value Per Share	3194.17	4105.42	5951.30	7845.89	8446.71	14957.10
Tangible Book Value	29,996	41,861	65,257	59,098	48,640	87,739
Tangible Book Value Per Share	2295.14	3203.95	4994.63	6485.40	8273.89	14937.67
Machinery	-	13,053	14,051	13,686	10,339	4,411
Construction In Progress	-	-	-	-	521.7	-

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 11, 2026

Data Sources Report a data error